Biolife Sciences Stock Probability of Future Pink Sheet Price Finishing Over 1.0E-4

BLFE Stock  USD 0.0001  0.00  0.00%   
BioLife Sciences' future price is the expected price of BioLife Sciences instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of BioLife Sciences performance during a given time horizon utilizing its historical volatility. Check out BioLife Sciences Backtesting, BioLife Sciences Valuation, BioLife Sciences Correlation, BioLife Sciences Hype Analysis, BioLife Sciences Volatility, BioLife Sciences History as well as BioLife Sciences Performance.
  
Please specify BioLife Sciences' target price for which you would like BioLife Sciences odds to be computed.

BioLife Sciences Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioLife Sciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioLife Sciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
BioLife Sciences generated a negative expected return over the last 90 days
BioLife Sciences has some characteristics of a very speculative penny stock
BioLife Sciences has high likelihood to experience some financial distress in the next 2 years
BioLife Sciences currently holds 398 K in liabilities. BioLife Sciences has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioLife Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, BioLife Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioLife Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioLife to invest in growth at high rates of return. When we think about BioLife Sciences' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (456.87 K) with profit before overhead, payroll, taxes, and interest of 0.
BioLife Sciences currently holds about 15.62 K in cash with (106.55 K) of positive cash flow from operations.

BioLife Sciences Technical Analysis

BioLife Sciences' future price can be derived by breaking down and analyzing its technical indicators over time. BioLife Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of BioLife Sciences. In general, you should focus on analyzing BioLife Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

BioLife Sciences Predictive Forecast Models

BioLife Sciences' time-series forecasting models is one of many BioLife Sciences' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary BioLife Sciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about BioLife Sciences

Checking the ongoing alerts about BioLife Sciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for BioLife Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
BioLife Sciences generated a negative expected return over the last 90 days
BioLife Sciences has some characteristics of a very speculative penny stock
BioLife Sciences has high likelihood to experience some financial distress in the next 2 years
BioLife Sciences currently holds 398 K in liabilities. BioLife Sciences has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioLife Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, BioLife Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioLife Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioLife to invest in growth at high rates of return. When we think about BioLife Sciences' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (456.87 K) with profit before overhead, payroll, taxes, and interest of 0.
BioLife Sciences currently holds about 15.62 K in cash with (106.55 K) of positive cash flow from operations.

Other Information on Investing in BioLife Pink Sheet

BioLife Sciences financial ratios help investors to determine whether BioLife Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLife with respect to the benefits of owning BioLife Sciences security.